Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PDCD4 | Q53EL6 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294148 | 1.00 | EPHX2 (0.69) | EPHX2ALDH1A1TSHRDAGLAMAPT | |
| SCHEMBL13805666 | 1.00 | EPHX2 (0.69) | EPHX2ALDH1A1TSHRDAGLAMAPT | |
| SCHEMBL4653040 | 1.00 | EPHX2 (0.69) | EPHX2ALDH1A1TSHRDAGLAMAPT | |
| SCHEMBL13295596 | 1.00 | EPHX2 (0.69) | EPHX2ALDH1A1TSHRDAGLAMAPT | |
| SCHEMBL16111818 | 0.88 | EPHX2 (0.73) | EPHX2ALDH1A1TSHRMAPTTRPV1 | |
| SCHEMBL16111819 | 0.88 | EPHX2 (0.73) | EPHX2ALDH1A1TSHRMAPTTRPV1 | |
| SCHEMBL23641349 | 0.83 | EPHX2 (0.64) | EPHX2TSHRDAGLAMAPT | |
| SCHEMBL5845119 | 0.83 | EPHX2 (0.64) | EPHX2TSHRDAGLAMAPT | |
| SCHEMBL19542362 | 0.83 | EPHX2 (0.64) | EPHX2TSHRDAGLAMAPT | |
| SCHEMBL14224912 | 0.82 | EPHX2 (0.65) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550617-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-06-23 | — | — | US | claimed |
| US-20080146663-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2008-06-19 | — | — | US | claimed |
| US-7732470-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732470-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2010-06-08 | — | — | US | disclosed |
| US-7550617-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550617-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080153889-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2008-06-26 | — | — | US | disclosed |
| US-20080146663-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2008-06-19 | — | — | US | disclosed |
| US-20080146663-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153889-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | REN, ALOX5, ALOX15B | EPHX2 9/4885ALDH1A1 1134/4885TSHR 3956/4885 |
| US-20080146663-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | REN, ALOX5, ALOX15B | EPHX2 8/4885ALDH1A1 1123/4885TSHR 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.